New genetic test aims to sharpen blood cancer diagnosis

NCT ID NCT07680868

Recruiting now Diagnosis Sponsor: Caris Science, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study looks at a new genetic test called Caris Chromoseq for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms). The test scans the entire genome to help classify the cancer and guide risk assessment. Researchers want to see if this test works as well as or better than current methods like cytogenetics, FISH, and NGS. The study involves 300 adults whose doctors have ordered the test, and it will compare results to standard testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Caris Chromoseq assay
What this could lead to: If successful, this test could provide faster and more detailed genetic information to help doctors classify blood cancers and guide treatment decisions.
What could go wrong: This is an observational study, not a treatment trial. The test's real-world benefits and accuracy compared to existing methods are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia disease myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA (AML) MYELODYSPLASTIC (MDS) / MYELOPROLIFERATIVE (MPN) DISEASES MYELODYSPLATIC SYNDROMES MYELOPROLIFERATIVE NEOPLASM

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Caris Life Sciences
RECRUITING

Phoenix, Arizona, 85040, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.